It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes.
1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06)
2. What were the major safety findings, including the effects on diabetic ketoacidosis and acute kidney injury? (2:44)
3. How do these compare to data from the other SGLT2 cardiovascular outcome trials? (3:50)
4. Why do you think this study has not shown a statistically significant effect on reducing the incidence of CV disease death and heart failure hospitalisations? (4:42)
5. With an increasing number of SGLT inhibitors available, what factors should be considered in choosing between them? (6:18)
Speaker disclosure: Christopher Cannon has received research grants from Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck and Pfizer and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Sanofi and Rhoshan.
Support: Interview commissioned and filming supported by Touch Medical Media.
Filmed in coverage of the ADA 2020 Virtual 80th Scientific Sessions.
Share this Video
Related Videos In Diabetes
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!